{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(18)"],"submitter":["Muglu H"],"pubmed_abstract":["<b>Objectives:</b> The objective of this study was to investigate the prognostic value of systemic inflammatory markers (SIMs)-namely, the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR)-on survival outcomes and treatment responses in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone (ABI) or enzalutamide (ENZA) therapy. <b>Methods:</b> In this two-center retrospective observational study, researchers analyzed clinical data from 106 patients diagnosed with mCRPC. The cut-offs for NLR and PLR were determined to be 2.83 and 156, respectively, and their effects on progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier and Cox regression analyses. Changes in SIMs before and after ABI/ENZA treatment were assessed using the Wilcoxon signed-rank test. <b>Results:</b> Lower NLR (≤2.83) and PLR (≤156) were significantly associated with longer PFS and OS; however, in multivariate analysis, only high PLR emerged as an independent adverse prognostic factor for OS (HR: 2.01; <i>p</i> = 0.026). Meanwhile, treatment response was an independent predictor of PFS, and no significant changes were observed in the mean platelet volume (MPV), platelet distribution width (PDW), or platelet-large cell ratio (P-LCR) after treatment. <b>Conclusions:</b> SIMs, such as NLR and especially PLR, may serve as practical and accessible tools for predicting survival in mCRPC patients; however, further prospective studies are warranted."],"journal":["Journal of clinical medicine"],"pagination":["6536"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12470515"],"repository":["biostudies-literature"],"pubmed_title":["The Prognostic Roles of Systemic Inflammatory Markers Before Abiraterone or Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer."],"pmcid":["PMC12470515"],"pubmed_authors":["Seker M","Seker Can L","Acıkgoz O","Hamdard J","Muglu H","Yıldız O","Bilici A","Sunger E","Olmez OF"],"additional_accession":[]},"is_claimable":false,"name":"The Prognostic Roles of Systemic Inflammatory Markers Before Abiraterone or Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer.","description":"<b>Objectives:</b> The objective of this study was to investigate the prognostic value of systemic inflammatory markers (SIMs)-namely, the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR)-on survival outcomes and treatment responses in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone (ABI) or enzalutamide (ENZA) therapy. <b>Methods:</b> In this two-center retrospective observational study, researchers analyzed clinical data from 106 patients diagnosed with mCRPC. The cut-offs for NLR and PLR were determined to be 2.83 and 156, respectively, and their effects on progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier and Cox regression analyses. Changes in SIMs before and after ABI/ENZA treatment were assessed using the Wilcoxon signed-rank test. <b>Results:</b> Lower NLR (≤2.83) and PLR (≤156) were significantly associated with longer PFS and OS; however, in multivariate analysis, only high PLR emerged as an independent adverse prognostic factor for OS (HR: 2.01; <i>p</i> = 0.026). Meanwhile, treatment response was an independent predictor of PFS, and no significant changes were observed in the mean platelet volume (MPV), platelet distribution width (PDW), or platelet-large cell ratio (P-LCR) after treatment. <b>Conclusions:</b> SIMs, such as NLR and especially PLR, may serve as practical and accessible tools for predicting survival in mCRPC patients; however, further prospective studies are warranted.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-05-02T03:16:37.304Z","creation":"2026-05-02T03:11:28.921Z"},"accession":"S-EPMC12470515","cross_references":{"pubmed":["41010740"],"doi":["10.3390/jcm14186536"]}}